

References

I-147

1. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. *J Clin Oncol*. 2015;33(25):2780-2788.
2. Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. *J Clin Oncol*. 2018;36(17):1658-1667.
3. Chesney J, Puzanov I, Collichio F, et al. Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. *Br J Cancer*. 2019;121:417-420.
4. Louie RJ, Perez MC, Jajja MR, et al. Real-world outcomes of talimogene laherparepvec therapy: a multi-institutional experience. *J Am Coll Surg*. 2019;228(4):644-649.
5. Talimogene laherparepvec In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated June 1, 2016.
6. Clinical Pharmacology™ Compendium.-2024. Tampa FL: Gold Standard, Inc. Talimogene laherparepvec.
7. Micromedex DrugDex Compendium®. 2024.Talimogene laherparepvec.
8. National Comprehensive Cancer Network (NCCN). Talimogene laherparepvec. NCCN Drugs and Biologics Compendium®. 2024.
9. Imlygic® (talimogene laherparepvec), suspension for intralesional injection [package insert]. BioVex, Inc. Thousand Oaks, CA. Revised 2/2023.